Intellia's CRISPR-based treatment for hereditary angioedema dramatically reduced swelling attacks in...
Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
Intellia's CRISPR-based treatment for hereditary angioedema dramatically reduced swelling attacks in a Phase 3 trial, setting stage for FDA approval.
Author: statnews.com
Read Original Article